Data / Form D filings / Scilex Holding Co
Scilex Holding Co: Form D filings
Scilex Holding Co, a biotechnology company in Palo Alto, CA, filed 2 Form D notices with the SEC between 2023 and 2025. The latest, on October 14, 2025, reports $2.7 million sold of a $2.7 million offering to 2 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 960 San Antonio Road, Palo Alto, CA, 94303
- Phone
- (650) 516-4310
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1820190
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 14, 2025 | New notice | $2,688,540 | $2,688,540 | 2 | Sep 30, 2025 | sec.gov | |
| Oct 5, 2023 | New notice | $101,875,000 | $101,875,000 | 1 | Sep 21, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Henry Ji | Executive Officer, Director | |
| Yue Alexander Wu | Director | |
| Jay Chun | Director | |
| Dorman Followwill | Director | |
| Stephen Ma | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Oct 13, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Scilex Holding Co reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.